Whether FDA says 'yes' or 'no' to an RMAT designation request may depend upon changes to the product during development and the extent of clinical data provided on different outcomes.
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
